These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 36062927)
1. Issues with Tissues: Trends in Tissue-Engineered Products in Clinical Trials in the European Union. Joyce K; Buljovcic Z; Rosic G; Kaszkin-Bettag M; Pandit A Tissue Eng Part B Rev; 2023 Feb; 29(1):78-88. PubMed ID: 36062927 [TBL] [Abstract][Full Text] [Related]
2. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe. Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211 [TBL] [Abstract][Full Text] [Related]
3. The Current State of Advanced Therapy Medicinal Products in the Czech Republic. Kočí Z; Boráň T; Krůpa P; Kubinová Š Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533 [TBL] [Abstract][Full Text] [Related]
4. Call for More Effective Regulation of Clinical Trials with Advanced Therapy Medicinal Products Consisting of or Containing Genetically Modified Organisms in the European Union. Beattie S; Hum Gene Ther; 2021 Oct; 32(19-20):997-1003. PubMed ID: 33843251 [TBL] [Abstract][Full Text] [Related]
5. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States. Iglesias-Lopez C; Obach M; Vallano A; Agustí A Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292 [TBL] [Abstract][Full Text] [Related]
6. Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving? Boráň T; Menezes-Ferreira M; Reischl I; Celis P; Ferry N; Gänsbacher B; Krafft H; Lipucci di Paola M; Sladowski D; Salmikangas P Hum Gene Ther Clin Dev; 2017 Sep; 28(3):126-135. PubMed ID: 28510497 [TBL] [Abstract][Full Text] [Related]
7. Advanced Therapy medicinal products for autologous chondrocytes and comparison of regulatory systems in target countries. Kim J; Park J; Song SY; Kim E Regen Ther; 2022 Jun; 20():126-137. PubMed ID: 35582708 [TBL] [Abstract][Full Text] [Related]
8. Regulation of tissue-engineered products in the European Union: where are we heading? Brévignon-Dodin L; Livesey F Regen Med; 2006 Sep; 1(5):709-14. PubMed ID: 17465739 [TBL] [Abstract][Full Text] [Related]
9. Bone tissue engineering - a field for new medicinal products? Lewandowska-Szumiel M; Wójtowicz J Curr Pharm Biotechnol; 2011 Nov; 12(11):1850-9. PubMed ID: 21902633 [TBL] [Abstract][Full Text] [Related]
10. Advanced therapy medicinal products: current and future perspectives. Hanna E; Rémuzat C; Auquier P; Toumi M J Mark Access Health Policy; 2016; 4():. PubMed ID: 27123193 [TBL] [Abstract][Full Text] [Related]
11. [European Marketing Authorisation: a long process. Experiences of small biotech companies with the ATMP regulation]. Buljovčić Z Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):831-8. PubMed ID: 21698536 [TBL] [Abstract][Full Text] [Related]
12. Business oriented EU human cell and tissue product legislation will adversely impact Member States' health care systems. Pirnay JP; Vanderkelen A; De Vos D; Draye JP; Rose T; Ceulemans C; Ectors N; Huys I; Jennes S; Verbeken G Cell Tissue Bank; 2013 Dec; 14(4):525-60. PubMed ID: 24052113 [TBL] [Abstract][Full Text] [Related]
13. Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials. Hanna E; Rémuzat C; Auquier P; Toumi M J Mark Access Health Policy; 2016; 4():. PubMed ID: 27570614 [TBL] [Abstract][Full Text] [Related]
14. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe. Schuessler-Lenz M; Herberts C; Reischl I; Ruiz S; Celis P; Beuneu C; Kjeken R; Timón M Adv Exp Med Biol; 2023; 1430():1-21. PubMed ID: 37526839 [TBL] [Abstract][Full Text] [Related]
15. Impact assessment of the European Clinical Trials Directive: a longitudinal, prospective, observational study analyzing patterns and trends in clinical drug trial applications submitted since 2001 to regulatory agencies in six EU countries. Hartmann M Trials; 2012 Apr; 13():53. PubMed ID: 22540886 [TBL] [Abstract][Full Text] [Related]
16. Prospects of Advanced Therapy Medicinal Products-Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives. Bakopoulou A J Endod; 2020 Sep; 46(9S):S175-S188. PubMed ID: 32950189 [TBL] [Abstract][Full Text] [Related]
17. Regulatory structures for gene therapy medicinal products in the European Union. Klug B; Celis P; Carr M; Reinhardt J Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782 [TBL] [Abstract][Full Text] [Related]
18. Regulatory challenges for autologous tissue engineered products on their way from bench to bedside in Europe. Ram-Liebig G; Bednarz J; Stuerzebecher B; Fahlenkamp D; Barbagli G; Romano G; Balsmeyer U; Spiegeler ME; Liebig S; Knispel H Adv Drug Deliv Rev; 2015 Mar; 82-83():181-91. PubMed ID: 25446139 [TBL] [Abstract][Full Text] [Related]
19. Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation. de Wilde S; Veltrop-Duits L; Hoozemans-Strik M; Ras T; Blom-Veenman J; Guchelaar HJ; Zandvliet M; Meij P Cytotherapy; 2016 Jun; 18(6):797-805. PubMed ID: 27068764 [TBL] [Abstract][Full Text] [Related]
20. From the Integrity of Potency Assays to Safe Clinical Intervention: Legal Perspectives. Roslin W; Mansnérus J Adv Exp Med Biol; 2023; 1420():151-163. PubMed ID: 37258789 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]